Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$35.01 USD
-1.15 (-3.18%)
Updated May 24, 2024 04:00 PM ET
After-Market: $34.99 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TARS 35.01 -1.15(-3.18%)
Will TARS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
Other News for TARS
12 Health Care Stocks Moving In Monday's Pre-Market Session
Tarsus Pharmaceuticals: A Strong Buy on Robust XDEMVY Sales and Promising Market Prospects
Tarsus Pharmaceuticals price target raised by $4 at H.C. Wainwright, here's why
Simple Ways To Stay With Trends: The Week In Charts
Tarsus Pharmaceuticals price target raised by $10 at Barclays, here's why